Figure 6.

Effects of (a) pre-incubating CEM, CEM_E1000 (E1000) and CEM_VBL (VBL) cells with various concentrations (0–30 µM) of unlabelled atazanavir (ATV) followed by the addition of [³H]ATV and (b) pre-incubating PBMCs with various concentrations (0–30 µM) of unlabelled ATV on the accumulation of [³H]ATV. Bars indicate mean ± SD (n = 4, with four independent observations from cultured CEM and its variant cells and n = 6 with four independent observations from each buffy coat PBMC sample). P values of *P < 0.05, **P < 0.01 and ***P < 0.001 indicate statistically significant differences in the CAR of [¹⁴C]LPV between control and drug-treated samples.